Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) Director William Hoffman sold 38,549 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $42.00, for a total value of $1,619,058.00. Following the completion of the sale, the director now owns 965,359 shares in the company, valued at $40,545,078. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
William Hoffman also recently made the following trade(s):
- On Tuesday, April 16th, William Hoffman sold 1,451 shares of Inari Medical stock. The shares were sold at an average price of $40.00, for a total value of $58,040.00.
- On Monday, March 18th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $41.13, for a total transaction of $1,645,200.00.
Inari Medical Price Performance
NARI stock opened at $42.03 on Friday. The firm has a 50 day simple moving average of $43.12 and a two-hundred day simple moving average of $53.68. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $71.85.
Look Who Fired the World’s Richest Man
From Banyan Hill Publishing | Ad
This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S.
And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.
Get the full story here.
Inari Medical (NASDAQ:NARI - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. The company had revenue of $132.10 million during the quarter, compared to analysts' expectations of $131.82 million. During the same quarter last year, the firm posted ($0.11) earnings per share. The firm's revenue was up 22.5% on a year-over-year basis. As a group, sell-side analysts expect that Inari Medical, Inc. will post -0.41 EPS for the current fiscal year.
Hedge Funds Weigh In On Inari Medical
Several institutional investors have recently modified their holdings of NARI. SG Americas Securities LLC bought a new position in Inari Medical during the third quarter valued at approximately $962,000. Asset Management One Co. Ltd. grew its holdings in shares of Inari Medical by 19.5% during the 3rd quarter. Asset Management One Co. Ltd. now owns 47,390 shares of the company's stock valued at $3,099,000 after purchasing an additional 7,720 shares during the last quarter. Brown Advisory Inc. raised its position in Inari Medical by 3.1% in the 3rd quarter. Brown Advisory Inc. now owns 1,446,931 shares of the company's stock worth $94,629,000 after purchasing an additional 43,657 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Inari Medical by 18.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,397 shares of the company's stock worth $745,000 after purchasing an additional 1,755 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Inari Medical by 13.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,958 shares of the company's stock valued at $1,632,000 after buying an additional 3,000 shares during the period. 90.98% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms recently commented on NARI. Wells Fargo & Company cut their price objective on shares of Inari Medical from $100.00 to $84.00 and set an "overweight" rating for the company in a report on Wednesday. Truist Financial cut their price target on Inari Medical from $61.00 to $52.00 and set a "hold" rating for the company in a report on Friday, March 22nd. Piper Sandler dropped their price objective on Inari Medical from $55.00 to $50.00 and set a "neutral" rating on the stock in a report on Wednesday. Needham & Company LLC reduced their price objective on shares of Inari Medical from $72.00 to $57.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Canaccord Genuity Group reduced their price target on shares of Inari Medical from $75.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Inari Medical presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.71.
View Our Latest Stock Analysis on Inari Medical
Inari Medical Company Profile
(
Get Free Report)
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
